KIST and M.O.P. to Collaborate on Development of Mass Cell Culture Platform (July 27, 2023)
- Date : 2023-10-11
- Views : 122
International Cooperation Team
KIST and M.O.P. to Collaborate on Development of Mass Cell Culture Platform
On July 27, KIST (President: Seok-Jin Yoon) held a signboard ceremony in recognition of the technology transfer and linking lab project establishment to develop a condensed electro-stimulation cell proliferation platform technology in collaboration with M.O.P.
The Linking Lab program is aimed at establishing joint laboratories with companies at KIST where R&D can be pursued for the rapid commercialization of consumer-centered technologies. The KIST-M.O.P. Linking Lab will be open for approximately two years, with the mission of developing a cell proliferation platform, a key technology for the development of cell therapy, by April 2025.
Cell therapy is a personalized treatment method that involves injecting living cells directly into patients, which has been attracting attention for its potential as a fundamental treatment for degenerative and rare and intractable diseases. It has the advantage of being able to quickly treat diseases without triggering an immune response, but it takes a long period of time to mass-produce cells. Researchers from both institutions are seeking to overcome this obstacle by collaborating on research to develop cell proliferation platforms.
M.O.P. CEO Hyung-il Choi commented, "Our mission is inspired by mother of pearl, a nanostructure commonly found in nature. We are conducting R&D so that excellent materials similar to mother of pearl may be implemented, and through this Linking Lab, we hope to commercialize a high-quality bone cell culture system for cell therapy."
Hyung-Seop Han, a principal researcher at KIST who is the PI for the research, said, "Our goal is to develop a platform that enables the production of high-quality mass cell cultures without dormancy by simulating the biological environment of our body through the application of continuous and stable direct current-type electrical stimulation to cell cultures. We anticipate that the completed platform can be applied to bone supports for dental implants or the production of customized artificial bones for patients."
Seok-Jin Yoon, the President of KIST, stated, "The condensed electro-stimulation cell proliferation technology that has been transferred to M.O.P. is a key technology in the development of biomaterials. We hope that, through collaborative research with companies such as M.O.P., KIST's fundamental technologies can successfully move beyond the research ‘Death Valley’ to reach the commercialization stage."